JP2022548694A5 - - Google Patents
Info
- Publication number
- JP2022548694A5 JP2022548694A5 JP2022517380A JP2022517380A JP2022548694A5 JP 2022548694 A5 JP2022548694 A5 JP 2022548694A5 JP 2022517380 A JP2022517380 A JP 2022517380A JP 2022517380 A JP2022517380 A JP 2022517380A JP 2022548694 A5 JP2022548694 A5 JP 2022548694A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- composition according
- labeled anti
- radioactively labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025160144A JP2026047359A (ja) | 2019-09-17 | 2025-09-26 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901290P | 2019-09-17 | 2019-09-17 | |
| US62/901,290 | 2019-09-17 | ||
| PCT/US2020/051324 WO2021055638A1 (en) | 2019-09-17 | 2020-09-17 | Radiolabeling of anti-cd45 immunoglobulin and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025160144A Division JP2026047359A (ja) | 2019-09-17 | 2025-09-26 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548694A JP2022548694A (ja) | 2022-11-21 |
| JP2022548694A5 true JP2022548694A5 (https=) | 2023-09-27 |
| JP7826190B2 JP7826190B2 (ja) | 2026-03-09 |
Family
ID=74883490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517380A Active JP7826190B2 (ja) | 2019-09-17 | 2020-09-17 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
| JP2025160144A Pending JP2026047359A (ja) | 2019-09-17 | 2025-09-26 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025160144A Pending JP2026047359A (ja) | 2019-09-17 | 2025-09-26 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12605472B2 (https=) |
| EP (1) | EP4031188A4 (https=) |
| JP (2) | JP7826190B2 (https=) |
| CN (1) | CN114728074A (https=) |
| AU (1) | AU2020350677A1 (https=) |
| CA (1) | CA3154732A1 (https=) |
| WO (1) | WO2021055638A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023137335A2 (en) * | 2022-01-11 | 2023-07-20 | Actinium Pharmaceuticals, Inc. | Methods for treating cd33-positive hematological malignancies |
| JP2025510189A (ja) | 2022-03-24 | 2025-04-14 | アクティニウム ファーマシューティカルズ インコーポレイテッド | ヒト化抗ｃｄ４５抗体 |
| WO2025064402A1 (en) * | 2023-09-22 | 2025-03-27 | St. Jude Children's Research Hospital, Inc. | Method for treating sickle cell disease by targeting senescent cells |
| CN119842630B (zh) * | 2024-12-31 | 2025-12-26 | 江苏为真生物医药技术股份有限公司 | 抗人cd45单克隆抗体杂交瘤细胞株及分泌抗体及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273738A (en) * | 1990-03-03 | 1993-12-28 | Fred Hutchinson Cancer Research Center | Radiation delivery to lymphoid and marrow tissues |
| EP3297684B1 (en) * | 2015-05-21 | 2020-12-23 | Actinium Pharmaceuticals, Inc. | Infusion administration of conjugated monoclonal antibodies |
| CN108026526B (zh) * | 2015-06-09 | 2023-05-12 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| AU2016274989A1 (en) | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| WO2017155937A1 (en) * | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| WO2019084273A1 (en) * | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES |
| US20230132400A9 (en) | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| WO2019136422A1 (en) * | 2018-01-08 | 2019-07-11 | Actinum Pharmaceuticals, Inc. | Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy |
| CA3137908A1 (en) | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
-
2020
- 2020-09-17 US US17/761,579 patent/US12605472B2/en active Active
- 2020-09-17 EP EP20864847.7A patent/EP4031188A4/en active Pending
- 2020-09-17 WO PCT/US2020/051324 patent/WO2021055638A1/en not_active Ceased
- 2020-09-17 CN CN202080078786.2A patent/CN114728074A/zh active Pending
- 2020-09-17 CA CA3154732A patent/CA3154732A1/en active Pending
- 2020-09-17 JP JP2022517380A patent/JP7826190B2/ja active Active
- 2020-09-17 AU AU2020350677A patent/AU2020350677A1/en active Pending
-
2025
- 2025-09-26 JP JP2025160144A patent/JP2026047359A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548694A5 (https=) | ||
| Knox et al. | Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. | |
| Pagel et al. | Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome | |
| MXPA02001398A (es) | Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20. | |
| US11912780B2 (en) | Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies | |
| JP7826190B2 (ja) | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 | |
| JP2023165952A (ja) | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 | |
| JP2026047359A5 (https=) | ||
| Jiang et al. | Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia | |
| JP2022519196A5 (https=) | ||
| TW202440171A (zh) | 治療前列腺癌之方法 | |
| Wang et al. | Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases | |
| Freedman et al. | Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation | |
| Yonekura | Current treatment strategies and emerging therapies for cutaneous lymphoma | |
| Geldof et al. | Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells | |
| TW202011948A (zh) | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 | |
| Soignet | Management of cancer-related anemia: epoetin alfa and quality of life | |
| Miura et al. | An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma | |
| Kitko et al. | Preparing the patient for HSCT: Conditioning regimens and their scientific rationale | |
| Draube et al. | German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies | |
| EP3958879A1 (en) | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases | |
| Sun et al. | Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus | |
| Qin | Development of targeted alpha particle therapy and identification of sensitizing strategies for efficacious Peptide Receptor Radionuclide Therapy (PRRT) in cancer | |
| HK40028713A (en) | Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies | |
| Billett et al. | Autologous bone marrow transplantation after a long first remission |